Zepbound

GLP-1 drugs: clinical trends, safety, and market shifts

247 clusters · 895 sources · last updated 1 day ago

Latest: GLP-1 medications transform obesity treatment approach

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

Expanded therapeutic research on metformin and semaglutide

12 clusters · 94 sources · last updated 2 days ago

Latest: Scientific studies explore grapes and semaglutide for longevity

Recent medical research has identified expanded therapeutic potential for diabetes and obesity medications, specifically metformin and semaglutide, regarding brain health, organ function, and aging. Studies from Baylor C

Eli Lilly retatrutide development and black market issues

8 clusters · 26 sources · last updated 4 days ago

Latest: Retatrutid shows significant weight loss in Phase 3 trials

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

Eli Lilly acquisition of Merida Biosciences

2 clusters · 19 sources · last updated 8 days ago

Latest: Eli Lilly to acquire Merida Biosciences for up to $2.875 billion

Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences, a biotechnology firm based in Cambridge, Massachusetts, for a total value of approximately $2.88 billion. The deal structure co

Corporate GLP-1 medication coverage trends

3 clusters · 9 sources · last updated 12 days ago

Latest: Bank of America maintains GLP-1 coverage for obesity

Major U.S. employers are adopting diverging strategies regarding the coverage of GLP-1 weight-loss medications, such as Ozempic, Wegovy, and Zepbound, due to rising costs. Bank of America has committed over $250 million